Baxter Travenol Laboratories, Inc.

World Health Organization

Richard G Buckles

Jan W Garber

Blood may be stored in vitro for a period of days at a reduced temperature in the container which also includes a sufficient quantity of an emulsion of anti-hemolytic agent to cause a reduction in the hemolysis of the stored blood, when compared with blood under similar storage conditions to the absence of the emulsion. Preferably, the emulsion may include a fatty ester containing at least two ester linkages each comprising a fatty hydrocarbon group, with the emulsion containing sufficient hemo-compatible surfactant to stabilize the emulsion.

Anti-hemolytic agent emulsions

A barrier contraceptive device and a method for preventing conception utilizing the device. The device comprises a torus of biocompatible material sized to fit in a vagina, structure--such as overlapping flaps--being provided with the torus for providing a primary barrier preventing direct ejaculation into the cervix while allowing fluid drainage from the cervix. The material forming the torus contains a spermicide and is operative to allow release of the spermicide to maintain an effective level of spermicide in the area between the torus and the cervix to kill any sperm that passes the primary barrier. The torus is constructed so that the spermicide is more readily releasable through the inner peripheral surface thereof than the outer peripheral surface thereof. The torus releases an effective amount of spermicide approximately over a period of time from the last day of menses until the start of the next menstrual period, the torus being inserted about the last day of menses and removed and disposed of at about the start of the next menstrual period.

Barrier contraceptive torus

Blood may be stored in vitro for a period of days at a reduced temperature in the container which also includes a sufficient quantity of an emulsion of anti-hemolytic agent to cause a reduction in the hemolysis of the stored blood, when compared with blood under similar storage conditions to the absence of the emulsion. Preferably, the emulsion includes a fatty ester containing at least two ester linkages each comprising a fatty hydrocarbon group, emulsified with sufficient hemo-compatible surfactant to stabilize the emulsion.

Growing community of inventors

Basel, Switzerland

Richard G Buckles